Although there is no significant difference in tumor volume between the 5-Fu-based CRT and lipotecan-based CRT regimen in vivo, the complete response rate of the lipotecan-based regimen is better than the 5-Fu-based CRT regimen, suggesting that lipotecan might induce better anticancer immunity to eradicate the residual tumors, especially the infiltration of CD8+ immune cells. This evidence concerns the gene CD8A and neoplasm.